![Risk of higher dose methotrexate for renal impairment in patients with rheumatoid arthritis | Scientific Reports Risk of higher dose methotrexate for renal impairment in patients with rheumatoid arthritis | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-75655-9/MediaObjects/41598_2020_75655_Fig1_HTML.png)
Risk of higher dose methotrexate for renal impairment in patients with rheumatoid arthritis | Scientific Reports
![Liver fibrosis with methotrexate — an overestimated risk? | Nature Reviews Gastroenterology & Hepatology Liver fibrosis with methotrexate — an overestimated risk? | Nature Reviews Gastroenterology & Hepatology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41575-023-00782-3/MediaObjects/41575_2023_782_Fig1_HTML.png)
Liver fibrosis with methotrexate — an overestimated risk? | Nature Reviews Gastroenterology & Hepatology
![High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial - The Lancet High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial - The Lancet](https://www.thelancet.com/cms/attachment/2001002082/2003731510/gr1.gif)
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial - The Lancet
![Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK | The BMJ Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK | The BMJ](https://www.bmj.com/content/bmj/381/bmj-2022-074678/F1.medium.jpg)
Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK | The BMJ
![PDF] The Hematologic Toxicity of Methotrexate in Patients with Autoimmune Disorders | Semantic Scholar PDF] The Hematologic Toxicity of Methotrexate in Patients with Autoimmune Disorders | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2ab79634a2bcc69ca68a7f41524c676026bd206a/2-Table1-1.png)
PDF] The Hematologic Toxicity of Methotrexate in Patients with Autoimmune Disorders | Semantic Scholar
![Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers | Nature Reviews Rheumatology Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers | Nature Reviews Rheumatology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fnrrheum.2016.175/MediaObjects/41584_2016_Article_BFnrrheum2016175_Fig2_HTML.jpg)